Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Diabetes
•
Nephrology
•
Endocrinology
•
End stage kidney disease
How do you adjust your management strategy to address the unique needs of anuric end-stage kidney disease patients when treating diabetic ketoacidosis?
Related Questions
What is your approach to managing osteoporosis in patients with end stage kidney disease?
How do you distinguish between primary and tertiary hyperparathyroidism in a patient with ESRD?
Should GLP1 R agonists be used as first line glucose lowering agents in patients with ESRD and DM?
Are recurrent UTIs a contraindication to SGLT2i use?
Do you recommend continuing SGLT2 inhibitors in patients with diabetic kidney disease and congestive heart failure who have been taking the medication for several years and later develop end stage kidney disease?
What is your approach to addressing severe dawn phenomenon in your patients with diabetes?
How do you counsel patients on semaglutide or tirzepatide in light of potential cancer risks?
What is your approach to differentiating diabetes insipidus from primary polydipsia in the outpatient setting?
How often do you check carnitine levels in your patients with end stage kidney disease on hemodialysis?
For a patient interested in home dialysis modalities, what are some key points that you discuss with them to help them make a decision on peritoneal dialysis versus home hemodialysis?
